Corporate Banner
Satellite Banner
Biomolecular Screening
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Reinventing Buffer Screening with Avacta’s Optim Technology

Published: Tuesday, March 18, 2014
Last Updated: Monday, March 17, 2014
Bookmark and Share
Optim system screen a wide range of buffer conditions quickly and cheaply.

Avacta’s Optim protein stability analysis technology is helping researchers at Manchester University to approach buffer selection in an entirely new way.

Dr Tom Jowitt, Manager of the University’s Biomolecular Analysis Core Facility, explained: “Academic institutions tend to work by word of mouth on protein projects, sticking to buffer conditions they are familiar with, or that have been used on previous projects within the laboratory. The buffers in use are often far from optimal for the protein of interest, but a lack of understanding of how to optimize buffer conditions means that these issues are rarely addressed.”

“As proteins become easier and easier to make in large quantities, we are trying to promote the concept of buffer screening, encouraging researchers to spend some time optimizing buffer conditions at the start of each project, and this is where Avacta’s Optim instrument comes in. Due to the low sample volume required for each analysis, the Optim system makes it easy to screen a wide range of buffer conditions relatively quickly and cheaply. We can now screen 10 or 20 buffer conditions for a protein of interest in a short space of time, which simply wasn’t plausible before we had the instrument, as the time and labour involved in performing multiple measurements using different technologies for each set of buffer conditions would have been prohibitive. This simple optimization process can have quite a significant impact on protein stability and aggregation rates, particularly for difficult to handle proteins such as those within extracellular matrix. Thanks to the Optim system, the benefits of buffer screening are being widely recognized throughout the Department and, with approximately 250 research groups, the potential knock-on benefits could be highly significant.”


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,200+ scientific posters on ePosters
  • More than 4,800+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.


Scientific News
Liquid Biopsies: Miracle Diagnostic or Next New Fad?
Thanks to the development of highly specific gene-amplification and sequencing technologies liquid biopsies access more biomarkers relevant to more cancers than ever before.
Drug Candidates Reduce Abnormal Protein Production
New drug candidates improve cell ability to catch miss-folded proteins that could cause deadly diseases.
Supercomputing and Drug Discovery
New biotech company uses supercomputer simulations to speed up drug discovery and biotech molecule development.
Preventing Breast Cancer with Hops
Study of hops extract suggests prevention of breast cancer through chemical pathway activation.
Treatment Advancement for Gaucher and Parkinson's Diseases
NIH scientists identify molecule that may act as a possible treatment of neurological diseases.
Biomunex Confirms Optimal Properties and Activity of BiXAb® Antibodies
Biomunex‘s Plug-and-Play bispecific antibodies demonstrated excellent in vitro properties and in vivo activity positively differentiating their BiXAb platform from competing formats.
Liquid Biopsy Predicts Colon Cancer Recurrence
Scientists have used a genetic test that spots bits of cancer-related DNA circulating in the blood to accurately predict the likelihood of the disease’s return in some — but not all — of a small group of patients with early-stage colon cancer.
New Treatment for Rare Blood Cancers
Drug called midostaurin showed promise in an international clinical trial led by a Stanford physician.
Biomarker for Parkinson's Disease Found in Urine Samples
Protein identified as Parkinson's biomarker sourced from patient's stored frozen urine samples.
Testing for Malaria or Cancer at Home
Chemist develops tech to save lives in rural Africa.
SELECTBIO

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,200+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,800+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!